Denmark’s Novo Nordisk is to invest £115m over 10 years in a new science research centre in Oxford, despite obvious post-brexit uncertainty, Novo Nordisk’s executive vice-president and chief science officer Mads Thomsen took a long term view.
“Obviously we think the Brexit decision was unfortunate. That being said, Oxford University has been around for 800 years so the academic excellence and our company’s ability to turn that into medicines hasn’t really changed,” he said.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.